The BCRF annual fundraiser focuses on tackling the toughest issues in breast cancer while celebrating remarkable achievements. New York…read more
Co-chaired by Giuseppe Curigliano and Alastair M. Thompson, IMPAKT 2014 will take place on 8-10 May 2014 in Brussels, Belgium. Jointly orga…read more
BIG decided to develop clear and user-friendly educational material to provide guidance for good laboratory practices for handling tissues. …read more
Recruitment has been achieved in 23 months four months ahead of the planned timelines, foreseen initially for a sample size of 3800 patients…read more
Several BIG researchers are co-authors of an article recently published in The Lancet regarding the latest findings from the HERA trial (BIG…read more
In a newly published video, Dr Martine Piccart describes the “Metastatic Breast Cancer GPS Programme," which aims to provide an intelligent …read more
TESARO, an oncology-focused biopharmaceutical company, Breast International Group (BIG) and the European Organization for Research and Treat…read more
Great progress has been made, but cancer incidence continues to grow. In Western countries, research and screening programs have successfully reduced the mortality rate but the number of patients diagnosed has actually increased over time (+66% since 1975). Today, a woman’s chance of getting breast cancer is 1 in 8.
Chaired by Dr Martine Piccart and Dr Aron Goldhirsch, BIG’s mission is to facilitate breast cancer research internationally. To fulfil its mission, BIG can count on a network of more than 3.000 hospitals and more than 10.000 doctors and researchers!
AURORA, our Metastatic breast cancer GPS
Academic programme “AURORA” (previously called PRISM-BC)
Metastatic cancer represents the leading cause of death among breast cancer patients, and little progress has been made until now. By using the latest technologies to “molecularly screen” patients tumours, the GPS project aims to analyse the mechanisms of resistance to treatment (why some patients’ tumours respond poorly), to understand the sensitivity to treatment (why some patients’ tumours respond well) and to track the natural progression of the disease. This will be the first large-scale international programme of its kind to focus on metastatic breast cancer, in the hope of significantly improving patients’ lives.
Breast cancer poses many challenges. Scientists have discovered that it is not just one disease, but that it has many variations! To understand any one of these variations and to develop effective treatments, it is necessary to study biological samples and data from thousands of patients. Access to so many patients at one time is only possible if researchers from around the globe commit to working together.
BIG brings together the best breast cancer researchers from around the world to collaborate to find a cure. Many people are still affected. The fight is far from over. Therefore, we need greater awareness from around the world to find out more.
Her Majesty The Queen of Belgium